Low Levels of APP Molecule Found in Patients With MS-related Fatigue
Multiple sclerosis (MS) patients with fatigue have significantly lower levels of amyloid precursor protein (APP) — a molecule…
Articles by Marta Figueiredo, PhD
Biogen, MedRhythms Working on Music Therapy for MS Gait Issues
Biogen has entered a licensing agreement to develop and potentially commercialize MedRhythms‘ investigational music-based digital therapy, MR-004, designed to help…
B-cell-depleting Therapies May Increase Risk of Psoriasis
Reports of psoriasis — an autoimmune skin disease that shares some biological processes with multiple sclerosis (MS) — are…
Uncertainties of MS Challenging in Scary Ways: UK Patient Survey
The uncertainties that accompany multiple sclerosis (MS) are among the biggest challenges faced by people with the disease, with two-thirds…
Survey Results Show Impact of MS in All Aspects of Life
Multiple sclerosis (MS) affects all aspects of life, from physical and mental health to relationships, and from work and finances…
Plegridy Found at Minimal Levels in Breast Milk, Small Study Reports
Plegridy (peginterferon beta-1a), an approved treatment for relapsing multiple sclerosis (MS), is detected at minimal concentrations in the…
New Imaging Techniques May Aid MS Diagnosis, Management
Physician-researchers at Cedars-Sinai Medical Center, in California, are developing brain and eye imaging techniques to improve the diagnosis and management…
Atara Planning Phase 3 Trials of ATA188 in Non-active SPMS, PPMS
Atara Biotherapeutics plans to launch two Phase 3 clinical trials of its investigational immunotherapy ATA188 in people with non-active,…
1st RRMS Patient Dosed in Phase 1/2 Trial of Immunotherapy IMCY-0141
A Phase 1/2 clinical trial evaluating Imcyse’s experimental therapy IMCY-0141 in people with relapsing-remitting multiple sclerosis (RRMS) has dosed its…
Australia Sets Aside $18M to Support MS Trials, EBV Research
The Australian government has announced that a record AU$18 million (about $13.5 million) from the Medical Research Future Fund…
8 More SPMS Patients Cleared for Foralumab Nasal Spray Treatment
Based on findings from the first two secondary progressive multiple sclerosis (SPMS) patients given foralumab nasal spray, an experimental…
New Blood Biomarker Technology May Help to Predict MS Activity
Simoa, a technology that detects relevant molecules in samples with up to 1,000 times greater sensitivity than conventional methods,…
#AAN2022 – Long-term Evobrutinib Safe, Effective in Relapsing MS
Long-term treatment with evobrutinib safely and effectively reduces the rate of relapses in adults with relapsing forms of…
National MS Society Details Steps to Achieving Pathways to Cures
The National Multiple Sclerosis Society (NMSS) has detailed its Pathways to Cures Roadmap and potential ways of addressing…
ProTEct-MS Trial Data Reinforce Previous Temelimab Studies
Higher doses of temelimab were generally safe and resulted in beneficial trends on key neurodegeneration markers in adults with…
Foralumab as Nasal Spray Safely, Effectively Treats 1st SPMS Patient
Six months of treatment with foralumab, an experimental nasal spray, safely and effectively improved motor and cognitive function while easing…
FDA Clears Leg-worn ‘Neural Sleeve’ to Aid Walking
Cionic has received authorization from the U.S. Food and Drug Administration (FDA) to market its lightweight, leg-worn Neural Sleeve…
MS Trust Survey: UK Nurses Treating ‘Unsustainable’ Numbers of Patients
The number of nurses in the U.K. with a specialty in multiple sclerosis (MS) care rose significantly between 2018 and…
Stem Cell Therapy NG-01 Shows Neuroprotective Effects in Trial
Administering the stem cell therapy NG-01 — designed to have neuroprotective and neuro-regenerative properties — directly into the spinal…
Masitinib Slows Disability Progression in PPMS, Non-active SPMS
Masitinib, AB Science’s experimental oral therapy, significantly slows disability progression in adults with primary progressive multiple sclerosis (PPMS)…
Bryostatin-1, Molecule to Protect Synapses, May Move Into MS Trials
Synaptogenix announced plans to advance bryostatin-1, its lead candidate, into clinical trials for multiple sclerosis (MS), marking the third neurological…
Fatigue Severity in MS Predicted by Shrinkage of Certain Brain Regions
Lower-than-normal volumes of certain brain regions at disease onset — indicating shrinkage, or atrophy, in those regions — are significantly…
EU Copaxone Label No Longer Advises Against Use During Breastfeeding
The label of Copaxone (glatiramer acetate) — an approved therapy for relapsing forms of multiple sclerosis (MS) — has been updated…
Weak Bones That Are Prone to Fractures May Affect Many With MS
Almost half of multiple sclerosis (MS) patients show reduced bone density (osteopenia) and about 17% have osteoporosis, a progressive…
Sweden, Like France, OKs Start of Masitinib Trial in Progressive MS
The Swedish Medical Products Agency has approved AB Science’s request to launch in the country a confirmatory Phase 3 clinical…
KAT7 Enzyme Spotted as Key to Training Immune System’s T-cells
KAT7, an enzyme known to regulate gene activity, is essential for the process of teaching immune T-cells to correctly identify…
Higher Risk of Long COVID Possible With MS, UK Study Suggests
Nearly a third of multiple sclerosis (MS)Â patients with COVID-19 experience symptoms that last at least one month, according to…
Cortrophin Gel Now Widely Available in US for Acute Relapses
ANI Pharmaceuticals has announced the full U.S. commercial availability of Cortrophin Gel (repository corticotropin injection), an injectable therapy…
COVID Booster May Benefit Patients on Anti-CD20 Therapy
Multiple sclerosis (MS) patients with weak immune responses to COVID-19 vaccines are more likely to respond successfully to the…
1st RRMS Patient Enrolled in ENSURE-2 Trial of Oral IMU-838
The ENSURE-2 Phase 3 clinical trial, evaluating Immunic Therapeutics’ experimental oral therapy IMU-838 (vidofludimus calcium) in adults with…